Tocilizumab treatment for refractory uveitis-related cystoid macular edema

Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases

(2012) Toshio Tanaka et al.   International Journal of Biological Sciences

Is Tocilizumab an Effective Option for Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis?

(2012) C. TAPPEINER et al.   JOURNAL OF RHEUMATOLOGY

The Impact of Macular Edema on Visual Function in Intermediate, Posterior, and Panuveitis

(2012) Simon R. J. Taylor et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Treatment of Refractory Uveitis with Adalimumab: A Prospective Multicenter Study of 131 Patients

(2012) Manuel Díaz-Llopis et al.   OPHTHALMOLOGY

Intraocular Interleukin-17 and Proinflammatory Cytokines in HLA-A29–Associated Birdshot Chorioretinopathy

(2011) Jonas J.W. Kuiper et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab

(2011) Toru Hirano et al.   Modern Rheumatology

Efficacy of Tocilizumab in Two Patients with anti-TNF-alpha Refractory Uveitis

(2011) Aurore Muselier et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses

(2010) Satoshi Hohki et al.   EXPERIMENTAL EYE RESEARCH

Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis

(2009) T. Yoshimura et al.   RHEUMATOLOGY

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES